M&A
J&J Agrees to Buy Ollin for $2.2 Billion; Blackstone Funds Trial
Johnson & Johnson agreed to buy Ollin Biosciences Inc. for $2.2 billion in cash upfront, adding a late-stage eye-disease drug to its pipeline and…
Archive
Johnson & Johnson agreed to buy Ollin Biosciences Inc. for $2.2 billion in cash upfront, adding a late-stage eye-disease drug to its pipeline and…